Alyssum Therapeutics is a biotechnology company that focuses on developing next-generation immunotherapies to modulate B cells.
Alyssum Therapeutics has raised $26.0M in total funding. The most recent round was Series A. The last funding was announced in October 2024.
Alyssum Therapeutics's investors include Accel, Navam Capital, Patrick Soon-Shiong, Famy Care.
Alyssum Therapeutics is headquartered in Cambridge, United States.
Alyssum Therapeutics is a biotechnology company that focuses on developing next-generation immunotherapies to modulate B cells.
Alyssum Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alyssum Therapeutics — Funding & Investors." VCBacked, October 23, 2024, https://www.vcbacked.co/company/alyssum-therapeutics. Accessed July 21, 2026.
VCBacked. (2024). Alyssum Therapeutics — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/alyssum-therapeutics
{{cite web |title=Alyssum Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alyssum-therapeutics |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated